Physician profile
Mark D Rickmeyer
NPI 1578509337
$2,268.94
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $155 · 2021: $443 · 2022: $444 · 2023: $394 · 2024: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761 · Entertainment: $20.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.56 |
| Entertainment | $20.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $944.77 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.18 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $139.95 | 2019-2024 | Xarelto, Spravato |
| Novo Nordisk INC | $136.88 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $123.23 | 2019-2024 | |
| Lilly USA, LLC | $106.86 | 2019-2024 | Mounjaro, Jardiance |
| Janssen Scientific Affairs, LLC | $91.59 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $81.95 | 2019-2024 | Breztri, Farxiga |
| Amgen INC. | $78.05 | 2019-2024 | Prolia, Evenity, Repatha |
| Allergan, INC. | $57.55 | 2020 | |
| Glaxosmithkline, LLC. | $50.45 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $47.94 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.85 | 2019-2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $27.33 | 2019 | |
| Optos, INC. | $20.03 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $19.05 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.01 | 2019 | |
| Abbott Laboratories | $17.94 | 2019 | |
| Astellas Pharma US INC | $17.49 | 2020 | |
| Tactile Systems Technology INC | $17.30 | 2023 | Entre Plus, Flexitouch Plus |
| Sanofi Pasteur INC. | $16.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,185,987.08 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rickmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.